Phase 3 SENOMAC randomized 2766 patients across five countries to completion ALND vs omission after up to two sentinel-node macrometastases, using overall survival as the primary endpoint. Five-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results